These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 25366363)

  • 1. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
    Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
    J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
    Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
    Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
    Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
    J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
    Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
    Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
    World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
    Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
    Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
    Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
    Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
    Kong DS; Nam DH; Kang SH; Lee JW; Chang JH; Kim JH; Lim YJ; Koh YC; Chung YG; Kim JM; Kim CH
    Oncotarget; 2017 Jan; 8(4):7003-7013. PubMed ID: 27690294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
    Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
    J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.